Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA. More information is available at http://www.bioinvent.com.

(1) "The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism," September 15, 2008, p.1.

(2) "Changes in Surgical Loads and Economic Burden of Hip and Knee Replacements in the US: 1997-2004," Sunny Kim, Arthritis & Rheumatism (Arthritis Care & Research), April 15, 2008; 59:4, pp. 481-488.

    ThromboGenics NV
    Gaston Geenslaan 1
    B-3001 Leuven
    Belgium
    Tel: +32(0)16-75-13-10
   http://www.thrombogenics.com

    BioInvent International AB (publ)
    Co. reg. No. 556537-7263,
    Address: Solvegatan 41
    Mailing address: SE-223 70 LUND
    Tel: +46(0)46-286-8
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MITI ) ("Micromet" or the "Company"), a ... of cancer,inflammation and autoimmune diseases, today announced that ... appointed Dr. Peter Johann, a,current member of the ... Company,s,audit committee. The appointment fills the vacancy left ...
... ALTO, Calif., Sept. 15 Varian, Inc.,(NasdaqGS: VARI) ... promoted,Sean M. Wirtjes, Vice President and Controller, to ... September 15, 2008. Wirtjes,assumes the Treasurer position from ... Vice President and Chief Financial Officer., The ...
... Inc.,(Amex: PIP ) a biodefense company ... countermeasures against chemical and,biological threats, announced today ... of Health and Human Services (DHHS) that ... anthrax vaccine,SparVax(TM), has completed a comprehensive technical ...
Cached Biology Technology:Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Varian, Inc. Board of Directors Makes Officer Changes 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 3PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 4
(Date:4/23/2014)... release is available in French and German . ... or female? In humans and other mammals, the difference between sexes ... It is present only in males, where the two sexual chromosomes ... the Y is ultimately responsible for all the morphological and physiological ... been the case. A very long time ago, the X and ...
(Date:4/23/2014)... Huntington,s disease, most in their mid-thirties and forties, ... behavioral decline within two decades. "Mutant" protein clusters, ... disease, have been the primary focus of therapies ... new research from Prof. Gerardo Lederkremer and Dr. ... Cell Research and Immunology, in collaboration with Prof. ...
(Date:4/23/2014)... A team of researchers in Korea who ... brains of nonhuman primates and assessed cell survival ... that the hNSCs had differentiated into neurons at ... The study will be published in a future ... currently freely available on-line as an unedited early ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Biology in the College of Arts and Science at ... 2011 Fitch Award for Excellence in Herpetology from the ... individuals who have demonstrated long-term excellence in the study ... of amphibian ecology and wetland conservation, Semlitsch is well-known ...
... When an animal gets too hot or too cold, or feels ... where it,s cooler or hotter, or to the nearest place where ... life? What can a plant do under similar circumstances? ... move to a more favorable spot. Yet they do respond ...
... TREW Marketing , a full-service firm focused on the ... for Engineers , a free guidebook for ... Available for download on TREW Marketing,s website , the ... and outlines the firm,s proven process to grow awareness ...
Cached Biology News:Ray Semlitsch receives 2011 Fitch Award for Excellence in Herpetology 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 3TREW Marketing Introduces Smart Marketing for Engineers, a Free Guidebook for Small Businesses Targeting Technical Audiences 2
The 50 ml Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: four 50 ml tubes. ,Magnets: Neodymium rare earth permanent magnets....
...
...
...
Biology Products: